Table 2.
Anti-malarial treatment prescribed
| Drug group/treatment | N | % |
| 1st line therapy (ART-AQ) | 1,217 | 43.0 |
| Combination therapy – other ACT | 418 | 14.8 |
| DHA+AQ | 240 | 8.5 |
| Artemether+AQ | 77 | 2.7 |
| Artemether+lumefantrine | 58 | 2.1 |
| DHA+pyrimethamine-sulphametopirazine | 13 | 0.5 |
| Artesunate+SP | 12 | 0.4 |
| DHA+SP | 6 | 0.2 |
| DHA+chloroquine | 5 | 0.2 |
| Artesunate+chloroquine | 3 | 0.1 |
| Artemether+pyrimethamine-sulphametopirazine | 1 | 0.04 |
| Artemether+quinine | 1 | 0.04 |
| Artesunate+ quinine | 1 | 0.04 |
| DHA+artemether+lumefantrine | 1 | 0.04 |
| Monotherapy – artemisinin based | 936 | 33.1 |
| DHA | 577 | 20.4 |
| Artesunate | 293 | 10.4 |
| Artemether | 55 | 1.9 |
| Artesunate/artemether | 10 | 0.4 |
| Artemether/DHA | 1 | 0.04 |
| Monotherapy – non-artemisinin | 260 | 9.2 |
| Amodiaquine | 133 | 4.7 |
| SP | 78 | 2.8 |
| Pyrimethamine-sulphametopirazine | 32 | 1.1 |
| Chloroquine | 14 | 0.5 |
| Quinine | 3 | 0.1 |
| Total | 2,831 |
DHA = dihydroartemisinine; AQ = amodiaquine; SP = sulphadoxine-pyrimethamine